

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/181403 A1

(51) International Patent Classification:

A61P 25/00 (2006.01) C07D 487/04 (2006.01)
C07D 409/14 (2006.01) C07D 487/08 (2006.01)
C07D 471/08 (2006.01) C07D 487/10 (2006.01)
C07D 471/10 (2006.01) A61K 31/496 (2006.01)

(21) International Application Number:

PCT/JP2024/006959

(22) International Filing Date:

27 February 2024 (27.02.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/487,122 27 February 2023 (27.02.2023) US
63/555,971 21 February 2024 (21.02.2024) US

(71) Applicant: OTSUKA PHARMACEUTICAL CO., LTD.
[JP/JP]; 2-9, Kanda Tsukasa-machi, Chiyoda-ku, Tokyo,
1018535 (JP).

(72) Inventors: LINGARD, Iain; Via Matteo da Campione,
11 Monza, 20900 (IT). PEZZATI, Bernardo; Via Pietro
Metastasio n.9, Florence, 50124 (IT). BONANOMI, Gio-
rgio; Via Ventura, 2 Verona, 37135 (IT). BURGIO, Gio-
vanna; Via Corno d'Aquilio, 31 Verona, 37124 (IT). BEL-
TRANI, Michela; Viale Nino Bixio n.21, Verona, 37126
(IT). CORBIOLI, Silvia; c/o Aptuit (Verona) srl, Campus
Levi-Montalcini, Via Alessandro Fleming, 4, Verona, 37135
(IT). LENZINI, Silvia; Via Bartolomeo Giuliani 4, Verona,
37134 (IT). KIM, Daniel; 15 Merion Court, Monroe Town-
ship, New Jersey, 08831 (US). BARNES, Laura; 385 Hol-
lowbrook Drive, Carlisle, Pennsylvania (US). AIHARA,
Keisuke; c/o OTSUKA PHARMACEUTICAL CO., LTD.,
3-2-27, Otedori, Chuo-ku, Osaka-shi, Osaka, 5400021 (JP).
SHINOHARA, Toshio; c/o OTSUKA PHARMACEUTI-
CAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Osaka-shi, Osa-
ka, 5400021 (JP). KIMURA, Naoji; c/o OTSUKA PHAR-
MACEUTICAL CO., LTD., 3-2-27, Otedori, Chuo-ku, Os-
aka-shi, Osaka, 5400021 (JP).

(74) Agent: YAMAO, Norihito et al.; AOYAMA & PART-
NERS, Osaka Umeda Twin Towers North, 8-1, Kaku-
da-cho, Kita-ku, Osaka-shi, Osaka, 5300017 (JP).


(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

(54) Title: PIPERAZINE-SUBSTITUTED BENZOTHIOPHENES FOR TREATMENT OF MENTAL DISORDERS



(57) Abstract: The present application relates to novel compounds of formula (I) which are prodrugs of brexpiprazole. The novel compounds of the invention, upon administration to a subject, undergo chemical conversion by one or more metabolic processes to release an active pharmacological agent in vivo. Brexpiprazole, sold under the Rexulti (registered trademark), is an atypical antipsychotic indicated for use as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults and the treatment of schizophrenia in adults and pediatric patients ages 13 years and older.

WO 2024/181403 A1